Prosecution Insights
Last updated: November 04, 2026

Mitochondria Emotion Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Mitochondria Emotion Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, KIFLE, BRUCK, who is the busiest examiner with 1 busiest examiner pending action. The portfolio's activity is limited to 1 distinct art unit, reflecting a concentrated focus on biotechnological innovations.

With 1 pending office action, the company's current prosecution efforts are concentrated on a single point of review. The outcome of this matter will be determined by the specific interpretations of KIFLE, BRUCK, making this examiner the primary focus for the applicant's legal strategy in this technology area. The 1 distinct examiner involved is the only person currently reviewing the company's patent claims in the Biotechnology & Pharmaceuticals sector.

The presence of 1 distinct art unit indicates that the technology is being evaluated within a specific division of the patent office. Because there is only 1 busiest examiner pending action, the company can focus its legal resources on addressing the specific prior art and legal issues raised by KIFLE, BRUCK. This focused approach allows for a highly targeted response but offers no internal benchmarks from other active cases.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KIFLE, BRUCK 1 79.3% +15.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18294389 CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF KIFLE, BRUCK —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18294389 CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF KIFLE, BRUCK —

Top Art Units

Art UnitApps
1624 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18294389 CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF KIFLE, BRUCK 1624 §103§112 Final Rejection — Pending Feb 01, 2024

Managing Mitochondria Emotion Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mitochondria Emotion Inc. have?

Mitochondria Emotion Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Mitochondria Emotion Inc. applications?

Bruck Kifle has the most, with 1 of Mitochondria Emotion Inc.'s pending office actions.

What technology area are Mitochondria Emotion Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month